ClinOne Revenue Soars 165% in First Half of 2021 as Pharma Speeds Adoption of Technology for Peer Referrals, eConsent, and Patient Empowerment in Global Clinical Research

DENVER, Aug. 11, 2021 /PRNewswire-PRWeb/ — ClinOne again experienced soaring demand for its technology platform during the first half of 2021 as global pharma continued to accelerate clinical research at an unprecedented pace. As a result, the company’s revenue skyrocketed 165% compared to the prior year, while adding 20 new sponsors, CROs, and sites to its customer base over the six months.

Platform growth was primarily driven by solutions for trusted patient referrals, enterprise eConsent, and a patient empowerment portal featuring virtual visits, Uber Health, and dosing and scheduling management. Demand and engagement were especially high in complex and challenging therapeutic areas, or those which require additional patient support, including oncology, rare disease, CNS, cardiovascular, and NASH.

“I root for every company in our industry, including direct competitors, because it means patients and families will benefit from technology that helps them manage their trial experience,” said Rob Bohacs (LinkedIn) ClinOne Founder and Chief Solutions Officer. “To see such strong demand for our solution in particular makes me extremely proud of the amazing team here. From watching them advocate for change, to pushing what’s possible with boundary-pushing solutions like connected devices, to going above and beyond to ensure customer success, I’m inspired every day by the people who make ClinOne a reality.”

As a true single platform that is easily configured and does not require much custom development, ClinOne is able to provide reliable global solutions that fit within existing budgets – while featuring the industry’s fastest implementation in an average 4 weeks. Highlights of the platform include…

MD Referral – Increases awareness of actively enrolling clinical trials by engaging healthcare providers and specialists in the local area who are likely to have qualified patients to refer. This raises awareness of the trial and connects care providers directly with enrolling sites, encouraging trusted referrals to help drive participation interest among patients – especially in oncology, rare disease, and other hard-to-recruit trials.

eConsent – ClinOne eConsent is a true enterprise solution used by sponsors, CROs, major site networks, and academic research institutions to manage the consent process for their trials. It features unrivaled remote capabilities to help patients and families make informed decisions, reduce site burden, and prevent document management errors that lead to costly audit findings.

Patient Empowerment – With virtual visits, Uber Health, dosing management, personal calendaring and more, ClinOne’s portal goes beyond engagement to enable patients to take control of their trial experience. ClinOne realizes no one participates in a trial alone, and provides the ability to share resources and information with caregivers, family members, loved ones, and other HPCs to create a care community throughout the trial and beyond.

To learn more about why demand for ClinOne technology continues to soar, visit

About ClinOne
The new era of clinical research has arrived. We help you lead the way with a single virtual platform to simplify patient enrollment, consent, data capture, compliance, and engagement. Featuring proven global logistics, the industry’s fastest implementation timelines, and an all-star team of senior executives, technologists and service professionals, ClinOne makes clinical research a little easier, every day, for patients and sites worldwide. How can we help you? Bring your challenges and find your solutions at

Media Contact

Brenda Nashawaty, ClinOne, +1 617-688-3253, [email protected]



ClinOne Revenue Soars 165% in First Half of 2021 as Pharma Speeds Adoption of Technology for Peer Referrals, eConsent, and Patient Empowerment in Global Clinical Research WeeklyReviewer

PR Newswire Science News

World Reviewer Staff
World Reviewer Staff
The first logical thought has to be "no way". I'm the World Observer! Ill find and share important news all day.

Latest articles

Earnings Disclosure

WeeklyReviewer earns primarily through affiliates and ads. We don’t encourage anyone to click on ads for any other purpose but your own. We recommend products and services often for our readers, and through many we will earn commissions through affiliate programs.

Related articles